Multidrug-resistant tuberculosis imported into low-incidence countries-a GeoSentinel analysis, 2008-2020.
MDR-TB
Travel
epidemiology
extensively drug-resistant tuberculosis
immigration
medical migration
migrant
Journal
Journal of travel medicine
ISSN: 1708-8305
Titre abrégé: J Travel Med
Pays: England
ID NLM: 9434456
Informations de publication
Date de publication:
27 08 2021
27 08 2021
Historique:
received:
21
02
2021
revised:
25
04
2021
accepted:
26
04
2021
pubmed:
15
5
2021
medline:
3
11
2021
entrez:
14
5
2021
Statut:
ppublish
Résumé
Early detection of imported multidrug-resistant tuberculosis (MDR-TB) is crucial, but knowledge gaps remain about migration- and travel-associated MDR-TB epidemiology. The aim was to describe epidemiologic characteristics among international travellers and migrants with MDR-TB. Clinician-determined and microbiologically confirmed MDR-TB diagnoses deemed to be related to travel or migration were extracted from GeoSentinel, a global surveillance network of travel and tropical medicine clinics, from January 2008 through December 2020. MDR-TB was defined as resistance to both isoniazid and rifampicin. Additional resistance to either a fluoroquinolone or a second-line injectable drug was categorized as pre-extensively drug-resistant (pre-XDR) TB, and as extensively drug-resistant (XDR) TB when resistance was detected for both. Sub-analyses were performed based on degree of resistance and country of origin. Of 201 patients, 136 had MDR-TB (67.7%), 25 had XDR-TB (12.4%), 23 had pre-XDR TB (11.4%) and 17 had unspecified MDR- or XDR-TB (8.5%); 196 (97.5%) were immigrants, of which 92 (45.8%) originated from the former Soviet Union. The median interval from arrival to presentation was 154 days (interquartile range [IQR]: 10-751 days); 34.3% of patients presented within 1 month after immigration, 30.9% between 1 and 12 months and 34.9% after ≥1 year. Pre-XDR- and XDR-TB patients from the former Soviet Union other than Georgia presented earlier than those with MDR-TB (26 days [IQR: 8-522] vs. 369 days [IQR: 84-827]), while patients from Georgia presented very early, irrespective of the level of resistance (8 days [IQR: 2-18] vs. 2 days [IQR: 1-17]). MDR-TB is uncommon in traditional travellers. Purposeful medical migration may partly explain differences in time to presentation among different groups. Public health resources are needed to better understand factors contributing to cross-border MDR-TB spread and to develop strategies to optimize care of TB-infected patients in their home countries before migration.
Sections du résumé
BACKGROUND
Early detection of imported multidrug-resistant tuberculosis (MDR-TB) is crucial, but knowledge gaps remain about migration- and travel-associated MDR-TB epidemiology. The aim was to describe epidemiologic characteristics among international travellers and migrants with MDR-TB.
METHODS
Clinician-determined and microbiologically confirmed MDR-TB diagnoses deemed to be related to travel or migration were extracted from GeoSentinel, a global surveillance network of travel and tropical medicine clinics, from January 2008 through December 2020. MDR-TB was defined as resistance to both isoniazid and rifampicin. Additional resistance to either a fluoroquinolone or a second-line injectable drug was categorized as pre-extensively drug-resistant (pre-XDR) TB, and as extensively drug-resistant (XDR) TB when resistance was detected for both. Sub-analyses were performed based on degree of resistance and country of origin.
RESULTS
Of 201 patients, 136 had MDR-TB (67.7%), 25 had XDR-TB (12.4%), 23 had pre-XDR TB (11.4%) and 17 had unspecified MDR- or XDR-TB (8.5%); 196 (97.5%) were immigrants, of which 92 (45.8%) originated from the former Soviet Union. The median interval from arrival to presentation was 154 days (interquartile range [IQR]: 10-751 days); 34.3% of patients presented within 1 month after immigration, 30.9% between 1 and 12 months and 34.9% after ≥1 year. Pre-XDR- and XDR-TB patients from the former Soviet Union other than Georgia presented earlier than those with MDR-TB (26 days [IQR: 8-522] vs. 369 days [IQR: 84-827]), while patients from Georgia presented very early, irrespective of the level of resistance (8 days [IQR: 2-18] vs. 2 days [IQR: 1-17]).
CONCLUSIONS
MDR-TB is uncommon in traditional travellers. Purposeful medical migration may partly explain differences in time to presentation among different groups. Public health resources are needed to better understand factors contributing to cross-border MDR-TB spread and to develop strategies to optimize care of TB-infected patients in their home countries before migration.
Identifiants
pubmed: 33987682
pii: 6274753
doi: 10.1093/jtm/taab069
pmc: PMC9638878
mid: NIHMS1845079
pii:
doi:
Substances chimiques
Antitubercular Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Medical Research Council
ID : G0701652
Pays : United Kingdom
Organisme : Cooperative Agreement
ID : U50CK00189
Organisme : NCEZID CDC HHS
ID : U50 CK000189
Pays : United States
Organisme : Public Health Agency of Canada
Organisme : Intramural CDC HHS
ID : CC999999
Pays : United States
Organisme : International Society of Travel Medicine
Organisme : CDC HHS
Pays : United States
Informations de copyright
© International Society of Travel Medicine 2021. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
Références
BMJ. 2018 Aug 23;362:k2738
pubmed: 30139910
Int J Tuberc Lung Dis. 2017 Jun 1;21(6):624-637
pubmed: 28482956
N Engl J Med. 2020 Mar 5;382(10):893-902
pubmed: 32130813
Emerg Infect Dis. 2016 Mar;22(3):518-21
pubmed: 26891089
Lancet Infect Dis. 2015 Oct;15(10):1193-1202
pubmed: 26116186
MMWR Surveill Summ. 2013 Jul 19;62:1-23
pubmed: 23863769
Euro Surveill. 2017 Mar 23;22(12):
pubmed: 28367797
Lancet Infect Dis. 2015 Dec;15(12):1485-91
pubmed: 26607130
Lancet. 2000 Aug 5;356(9228):461-5
pubmed: 10981889
J Travel Med. 2010 Jul-Aug;17(4):233-42
pubmed: 20636596
J Travel Med. 2019 Feb 1;26(2):
pubmed: 30726941
Clin Infect Dis. 2001 Oct 15;33(8):1393-6
pubmed: 11565081
Eur Respir J. 2015 Apr;45(4):1081-8
pubmed: 25395035
Int J Tuberc Lung Dis. 2014 Dec;18(12):1479-84
pubmed: 25517815
Lancet Infect Dis. 2018 Jan;18(1):76-84
pubmed: 29198911
Lancet Infect Dis. 2016 Jun;16(6):642-643
pubmed: 27301923
J Travel Med. 2016 Mar;23(3):
pubmed: 27358971
Int J Tuberc Lung Dis. 2011 Jan;15(1):38-43
pubmed: 21276294
Travel Med Infect Dis. 2016 Nov - Dec;14(6):588-590
pubmed: 27913312
Lancet Infect Dis. 2017 May;17(5):e144-e158
pubmed: 28291722
Euro Surveill. 2013 Aug 15;18(33):20555
pubmed: 23968874
J Travel Med. 2015 Dec 18;23(1):
pubmed: 26684486
Br J Dis Chest. 1984 Jul;78(3):248-53
pubmed: 6743520
Med Mal Infect. 2016 Feb;46(1):52-5
pubmed: 26809373